Point72 Asset Management L.P. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Point72 Asset Management L.P. acquired a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 83,077 shares of the company's stock, valued at approximately $1,097,000. Point72 Asset Management L.P. owned about 0.05% of Neumora Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Callan Capital LLC increased its stake in Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company's stock worth $6,500,000 after buying an additional 456,207 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Neumora Therapeutics by 79.5% during the second quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company's stock valued at $1,099,000 after purchasing an additional 49,527 shares in the last quarter. Rhumbline Advisers grew its holdings in Neumora Therapeutics by 488.3% during the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company's stock valued at $1,015,000 after buying an additional 85,706 shares in the last quarter. Auour Investments LLC bought a new stake in Neumora Therapeutics in the 3rd quarter worth approximately $3,302,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock worth $9,224,000 after acquiring an additional 406,891 shares in the last quarter. 47.65% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Robert A. Lenz sold 5,563 shares of the firm's stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now owns 322,966 shares in the company, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,400 shares of company stock valued at $686,361. Company insiders own 26.40% of the company's stock.

Neumora Therapeutics Stock Up 0.7 %

Shares of NASDAQ:NMRA traded up $0.07 during trading on Wednesday, hitting $10.46. The stock had a trading volume of 388,886 shares, compared to its average volume of 741,664. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -5.56 and a beta of 3.37. The stock has a 50-day simple moving average of $12.25 and a two-hundred day simple moving average of $11.50.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter last year, the business posted ($1.14) EPS. As a group, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Royal Bank of Canada restated an "outperform" rating and set a $29.00 target price on shares of Neumora Therapeutics in a research report on Friday, November 22nd. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Needham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. downgraded Neumora Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $21.67.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.